rs111033415
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The ENST00000409709.9(MYO7A):c.1344-2A>G variant causes a splice acceptor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000139 in 1,443,116 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
ENST00000409709.9 splice_acceptor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYO7A | NM_000260.4 | c.1344-2A>G | splice_acceptor_variant | ENST00000409709.9 | NP_000251.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYO7A | ENST00000409709.9 | c.1344-2A>G | splice_acceptor_variant | 1 | NM_000260.4 | ENSP00000386331 | ||||
MYO7A | ENST00000409619.6 | c.1311-2A>G | splice_acceptor_variant | 1 | ENSP00000386635 | |||||
MYO7A | ENST00000458637.6 | c.1344-2A>G | splice_acceptor_variant | 1 | ENSP00000392185 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000139 AC: 2AN: 1443116Hom.: 0 Cov.: 31 AF XY: 0.00000140 AC XY: 1AN XY: 715696
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 17, 2022 | Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 15823922, 31479088) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 25, 2023 | This sequence change affects an acceptor splice site in intron 12 of the MYO7A gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MYO7A are known to be pathogenic (PMID: 8900236, 25404053). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with autosomal recessive deafness and/or autosomal recessive Usher syndrome (PMID: 15823922, 26445815, 27460420). This variant is also known as c.1244-2A>G. ClinVar contains an entry for this variant (Variation ID: 43143). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Usher syndrome type 1;C1838701:Autosomal recessive nonsyndromic hearing loss 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Feb 08, 2017 | - - |
Usher syndrome type 1B Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Feb 25, 2021 | - - |
Nonsyndromic genetic hearing loss Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | INGEBI, INGEBI / CONICET | Jul 15, 2021 | Based on ACMG/AMP guidelines and Hearing Loss Expert Panel specific criteria:The c.1344-2 A>G variant in MYO7A gene is absent from population databases meeting PM2. This type of variant is predicted to generate a lost of the aceptor splicing site in MYO7A gene affecting gene MYO7A, which is a known mechanism of disease, PVS1. The c.1344-2 A>G has been identified in trans with a pathogenic variant in an Ushers patient with altered balance (PMID:15823922). Besides, it was identified in homocygous state in two different families (one with severe-profound non-syndrmic hearing loss and the other with Usher Syndromce) and an sporadic case with Usher Syndrome; PMID: 26445815, 27460420.); PP4. In thi work, c.1344-2 A>G was detected in trans with a pathogenic variant in MYO7A gene in a child with non-syndormic hearing loss (ophtalmic features could appear in the youth); PM3_S. Taking into account all the information together: PM2, PVS1, PM3_S, PP4 the variant is classified as Pathogenics for non-syndromic hearing loss and Usher Syndrome. - |
Rare genetic deafness Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 12, 2017 | The c.1344-2A>G variant in MYO7A has been reported in four individuals with Ushe r syndrome (Maubaret 2005, LMM data). One of them was homozygous for the variant and three other individuals were compound heterozygous with a second pathogenic MYO7A variant. This variant has not been identified in large population studies . In addition, this variant occurs in the invariant region (+/- 1/2) of the spli ce consensus sequence and is predicted to cause altered splicing leading to an a bnormal or absent protein. In summary, this variant meets criteria to be classif ied as pathogenic for Usher syndrome in an autosomal recessive manner. - |
Ear malformation Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Kariminejad - Najmabadi Pathology & Genetics Center | Jul 10, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at